Nasal Administration of Anti-CD3 mAb (Foralumab) Downregulates NKG7 and Increases TGFB1 and GIMAP7 Expression in T Cells in Subjects with COVID-19

0
269
Using serum proteomics and RNA-sequencing, the authors investigated the immune changes in patients treated with nasal Foralumab.
[Proceedings Of The National Academy Of Sciences Of The United States Of America]
Full Article